Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Pulmatrix News

    1,90 € 0,00% +0,00 €
    08:00:45 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DWEE
    ISIN: US74584P3010
    US-Symbol: PULM
    Typ: Aktie

    Pulmatrix News

    28.03.24 - PR Newswire
    Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
    Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update PR Newswire
    08.01.24 - PR Newswire
    Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
    Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of ...
    09.11.23 - PR Newswire
    Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
    Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    19.09.23 - PR Newswire
    Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
    Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine PR Newswire
    23.08.23 - PR Newswire
    Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
    Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole PR Newswire
    10.08.23 - PR Newswire
    Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
    Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    11.07.23 - PR Newswire
    Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
    Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine PR Newswire
    15.06.23 - PR Newswire
    Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society
    Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society PR Newswire
    24.05.23 - PR Newswire
    Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
    Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention PR Newswire
    12.05.23 - PR Newswire
    Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
    Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    02.05.23 - PR Newswire
    Pulmatrix Supports World Asthma Day 2023
    Pulmatrix Supports World Asthma Day 2023 PR Newswire
    30.03.23 - PR Newswire
    Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
    Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update PR Newswire
    25.01.23 - PR Newswire
    Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
    Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" PR Newswire
    23.01.23 - PR Newswire
    Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology PR Newswire
    04.01.23 - PR Newswire
    Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
    Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine PR Newswire
    10.11.22 - PR Newswire
    Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
    Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
    26.09.22 - PR Newswire
    Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
    Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine PR Newswire
    08.08.22 - PR Newswire
    Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
    Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
    12.07.22 - PR Newswire
    Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
    Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine New inhaled formulation of dihydroergotamine (DHE) intended for acute migraine therapy ...
    12.05.22 - PR Newswire
    Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
    Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire

    Newssuche

    Videos

    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »